Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic–pituitary–adrenocortical axis

Neuropsychopharmacology

Volumn 28, Issue 6, 2003, Pages 1056-1067

  Bachmann, Cornelius G ^a   Linthorst, Astrid C E ^a   Holsboer, Florian ^a   Reul, Johannes M H M ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antagonist; Antidepressant drugs; Glucocorticoid receptor; HPA axis; Major depression; Mineralocorticoid receptor; Steroids; Stress

Indexed keywords

GLUCOCORTICOID RECEPTOR; HORMONE ANTAGONIST;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM; RAT; WISTAR RAT;

ANIMALS; HORMONE ANTAGONISTS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID;

EID: 0038565455     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300158     Document Type: Article

References (67)

1. Bamberger CM, Chrousos GP (1995). The glucocorticoid receptor and RU 486 in man. Ann NY Acad Sci761: 296-310.
2. Belanoff KB, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001). Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol21: 516-521.
3. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr (1992). The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosin hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res572: 117-125.
4. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M (1991). Long-term antidepressant administration alters corticotropinreleasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest87: 831-837.
5. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O et al(1998). Molecular basis of agonism and antagonism in the estrogen receptor. Nature389: 753-758.
6. Cadepond F, Ulmann A, Baulieu EE (1997). RU 486 (mifepristone): mechanism of action and clinical uses. Annu Rev Med48: 129-156.
7. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR et al(1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698.
8. Dallman MF, Akana SF, Cascio CS, Darlington DN, Jacobson L, Levin N (1987). Regulation of ACTH secretion: variation on a theme of B. Prog Horm Res43: 113-173.
9. De Kloet ER, De Kock S, Schild V, Veldhuis HD (1988). Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary-adrenal axis at different sites. Neuroendocrinology47: 109-115.
10. De Kloet ER, McEwen BS (1976). A putative glucocorticoid receptor and a transcortin-like macromolecule in pituitary cytosol. Biochim Biophys Acta421: 115-123.
11. De Kloet ER, Reul JMHM (1987). Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology12: 83-105.
12. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998). Brain corticosteroid receptor balance in health and disease. Endocr Rev19: 269-301.
13. De Nicola AF, Tornello S, Weisenberg I, Fridman O, Birmingham MK (1981). Uptake and binding of 3H-aldosterone by the anterior pituitary and brain regions in adrenalectomized rats. Horm Metab Res13: 103-106.
14. Deraedt R, Bonnat C, Busigny M (1985). Pharmacokinetics of RU 48. In: Baulieu EE, Segal S (eds). The Antiprogestin Steroid RU 486 and Human Fertility Control. Plenum Press: New York. pp 103-122.
15. Fuxe K, Wilkström AC, Okret S, Agnati LF, Härfstrand A, Yu ZY et al(1985). Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology117: 1803-1812.
16. Gagne D, Pons M, Philibert D (1985). RU 38486: a potent antiglucocorticoid in vitro and in vivo. J Steroid Biochem23: 247.
17. Gaillard RC, Riondell A, Muller AF, Herrmann W, Baulieu EE (1984). RU 486: a steroid with antiglucocortcosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of the day.Proc Natl Acad Sci USA81: 3879-3882.
18. Gesing A, Bilang-Bleuel A, Droste SK, Linthorst ACE, Holsboer F, Reul JMHM (2001). Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin releasing hormone. J Neurosci21: 4822-4829.
19. Gesing A, Reul JMHM (2003). Chronic treatment with antidepressant drugs results in attenuation of hypothalamic-pituitary-adrenocortical responses irrespective of their neuropharmacological profile. In preparation.
20. Gruol DJ, Altschmied J (1993). Synergistic induction of apoptosis with glucocorticoids and 30, 50-cyclic adenosine monophosphate reveals agonist activity by RU 486. Mol Endocrinol7: 104-113.
21. Havel PJ, Busch BL, Curry DL, Johnson PR, Dallman MF, Stern JS (1996). Predominantly glucocorticoid agonist actions of RU 486 in young specific-pathogen-free Zucker rats. Am J Phys271 (Pt 2): R710-R717.
22. Herman JP, Patel PD, Akil H, Watson SJ (1989). Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol Endocrinol3: 1886-1894.
23. Herman JP, Spencer R (1998). Regulation of hippocampal glucocorticoid receptor gene transcription and protein expression in vivo. J Neurosci18: 7462-7473.
24. Heuser IJ, Wark H-J, Borchardt D, Hermle L (1990). Limbic-hypothalamic-pituitary-adrenal axis dysfunction in elderly depressed patients. Clin Neuropharmacol13(Suppl 2): 188-190.
25. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology23: 477-501.
26. Holsboer F, Liebl R, Hofschuster E (1982). Repeated dexametha-sone suppression test during depressive illness. Normalization of test results compared with clinical improvement. J Affect Dis4: 93-101.
27. Holsboer-Trachsler E, Stohler R, Hatzinger M (1991). Repeated administration of the combined dexamethasone/hCRH stimulation test during treatment of depression. Psychiatry Res38: 163-171.
28. Jasper MS, Engeland WC (1994). Splanchnic neural activity modulates ultradian and circadian rhythms in adrenocortical secretion in awake rats. Neuroendocrinology59: 97-109.
29. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, Chrousos GP (1987). Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone RU 486 in man. J Pharmacol Exp Ther241: 401-406.
30. Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, gren SO et al(1988). Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryp-tamine nerve cell groups of the rostral ventromedial medulla. J Neural Trans73: 191-203.
31. Korte SM, Bouws GAH, Bohus B (1993). Central actions of corticotropin-releasing hormone on behavioral, neuroendocrine, and cardiovascular regulation: brain corticoid receptor involvement. Horm Behav27: 167-183.
32. Lähteenmäki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L et al(1987). Pharmacokinetics and metabolism of RU 48. J Steroid Biochem27: 859-863.
33. Lamberts SW, Koper JW, de Jong FH (1991). The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab73: 187-191.
34. Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL, Fleisher TA (1990). Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab71: 1474-1480.
35. Lin W, Celik A, Paczynski RP, Hsu CY, Powers WJ (1999). Quantitiative magnetic resonance imaging in experimental hypercapnia: improvement in the relation between changes in brain R2 and the oxygen saturation of venous blood after correction for changes in cerebral volume. J Cereb Blood Flow Metab19: 853-862.
36. Linkowski P, Mendlewicz J, Leclerq R, Brasseur M, Hubain P, Goldstein J et al(1985). The 24-hour profile of adrenocortico-trophin and cortisol in major depressive illness. J Clin Endocrinol Metab61: 429-438.
37. Lowry OH, Rosebrough NJ, Farr AL, Randall NJ (1951). Protein measurements with the Folin phenol reagent. J Biol Chem193: 265-275.
38. McDonnell DP, Shahbahz MM, Vegeto E, Goldman ME (1994). The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol48: 425-432.
39. Gerlach JL, McEwen BS (1972). Rat brain binds adrenal steroid hormone: radioautography of hippocampus with corticosterone. Science175: 1133-1136.
40. Moguilewsky M, Raynaud JP (1980). Evidence for specific mineralocorticoid receptor in rat pituitary and brain. J Steroid Biochem12: 309-314.
41. Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SSC (1987). Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J Clin Endocrinol Metab65: 962-968.
42. Murphy BE, Ghadirian AM, Dhar V (1998). Neuroendocrine responses in patients to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry43: 279-286.
43. Nicholson S, Lin JH, Mahmoud S, Campbell E, Gillham B, Jones M (1985). Diurnal variation in responsiveness of the hypothalamo-pituitary-adrenocortical axis of the rat. Neuroendocrinology40: 217-224.
44. Peeters BW, Tonnaer JA, Groen MB, Broekkamp CL, van der Voort HA, Schoonen WG et al (1998). Glucocrticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. printed by NV Organon, Oss, The Netherlands.
45. Porsolt RD, Anton G, Blavat N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol47: 379-391.
46. Ratka A, Sutanto W, Bloemers M, De Kloet ER (1989). On the role of brain mineralocorticoid (Type I) and glucocorticoid (Type II) receptors in neuroendocrine regulations. Neuroendocrinology50: 117-123.
47. Rees HD, Stumpf WE, Sar M, Petrusz P (1977). Autoradiographic studies of 3H-dexamethasone uptake in immunocytochemically characterized cells of the rat pituitary. Cell Tissue Res182: 347-356.
48. Reul JMHM, De Kloet ER (1985). Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology117: 2505-2512.
49. Reul JMHM, De Kloet ER (1986). Anatomical resolution of two types of corticosterone receptor sites in rat brain with in vivo autoradiography and computerized image analysis. J Steroid Biochem24: 269-272.
50. Reul JMHM, de Kloet ER, van Sluys FJ, Rijnberg A, Rothuizen J (1990). Binding characteristics of mineralocorticoid and glucocorticoid receptors in dog brain and pituitary. Endocrinology127: 907-915.
51. Reul JMHM, Gesing A, Droste S, Stec ISM, Weber A, Bachmann C et al(2000). The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol405: 235-249.
52. Reul JMHM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F (1994). Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology60: 509-519.
53. Reul JMHM, Pearce PT, Funder JW, Krozowski ZS (1989). Type I and Type II corticosteroid receptor gene expression in the rat: effect of adrenalectomy and dexamethasone administration. Mol Endocrinol3: 1674-1680.
54. Reul JMHM, Stec I, Soder M, Holsboer F (1993). Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology133: 312-320.
55. Reul JMHM, van den Bosch FR, De Kloet ER (1987). Differential response of type I and type II corticosteroid receptor to changes in plasma steroid level and circadian rhythmicity. Neuroendocrinology45: 407-412.
56. Reus VI, Wolkowitz OM (2001). Antiglucocorticoid drugs in the treatment of depression. Expert Opin Invest Drugs10: 1789-1796.
57. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF (1973). Disrupted 24-hr patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry28: 19-24.
58. Schneider F, Gur RE, Alavi A, Seligman ME, Harper Mozley L, Smith RJ et al(1996). Cerebral blood flow changes in limbic regions induced by unsolvable anagram tasks. Am J Psychiatry153: 206-212.
59. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al(1998). The structural basis of estrogen/coactivator recogni- tion and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
60. Spencer RL, Kim PJ, Kalman BA, Cole MA (1998). Evidence for mineralocorticoid receptor facilitation of glucocorticoid recep¬tor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 139: 2718-2727.
61. Steckler T, Holsboer F, Reul JMHM (1999). Glucocorticoids and depression. Balli 13: 107-124.
62. Trapp T, Holsboer F (1995). Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215: 286-291.
63. Van der Lely A, Foeken K, Van der Mast RC, Lamberts SW (1991). Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114: 143-144.
64. Van Eekelen JAM, Jiang W, De Kloet ER, Bohn MC (1988). Distribution of the mineralocorticoid and the glucocorticoid receptor mRNAs in the rat hippocampus. J Neurosci Res 21: 88-94.
65. Van Haarst AD, Oitzl MS, De Kloet ER (1997). Facilitation of feedback inhibition through blockade of glucocorticoid recep¬tors in the hippocampus. Neurchem Res 22: 1323-1328.
66. Van Haarst AD, Oitzl MS, Workel JO, de Kloet ER (1996). Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endo¬crinology 137: 4935-4943.
67. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R et al (1999). Antiglucocorticoid treatment of depression: double¬blind ketoconazole. Biol Psychiatry 45: 1070-1074.